HIF-2alpha-mediated activation of the epidermal growth factor receptor potentiates head and neck cancer cell migration in response to hypoxia.
Despite their individual key roles in promoting head and neck squamous cell carcinoma (HNSCC) progression and treatment resistance, little is known about the impact of intratumoral hypoxia on the activity of the epidermal growth factor receptor (EGFR) signaling pathway in this cancer type. Here, we show that in highly EGFR-expressing HNSCC cells, hypoxic stress triggers the activation of the EGFR and downstream targets, including Akt and phospholipase C (PLC) gamma1. In support of these findings, we also demonstrate that EGFR activation takes place within hypoxic foci in a subset of human HNSCC tissues. Whereas hypoxia had no major effect on HNSCC cell proliferation, it markedly altered tumor cell shape by inducing morphological changes consistent with a more spindle-shaped, fibroblast-like morphology together with an enhanced migratory capacity. We found that hypoxia-induced EGFR activation and cell migration could be prevented by targeting EGFR signaling with the tyrosine kinase inhibitor tyrphostin, the phospholipase C inhibitor U73122, or by inhibiting the expression of the alpha subunit of hypoxia-inducible factor 2 via RNA interference or the topoisomerase II inhibitor etoposide. Our results position hypoxia-inducible factor-2alpha as a novel regulator of EGFR activation under low oxygen conditions, and suggest that hypoxia-induced EGFR signaling may promote a more aggressive phenotype in a fraction of HNSCC tumors. Because EGFR continues in the forefront as a highly attractive target in clinical oncology, further studies are warranted to define the mechanistic and therapeutic implications of the hypoxic response relative to the EGFR signaling pathway in head and neck cancer.
Wang
Xin
X
Department of Oncology and Diagnostic Sciences, Dental School, University of Maryland, Baltimore, MD 21201, USA.
Schneider
Abraham
A
D000199:Actins / Q000032:analysis; D051792:Basic Helix-Loop-Helix Proteins / Q000502:physiology*; D002294:Carcinoma, Squamous Cell / Q000473:pathology*; D015687:Cell Hypoxia; D045744:Cell Line, Tumor; D002465:Cell Movement; D066246:ErbB Receptors / Q000502:physiology*; D006258:Head and Neck Neoplasms / Q000473:pathology*; D006801:Humans; D051966:Phospholipase C gamma / Q000502:physiology; D010766:Phosphorylation; D051794:Von Hippel-Lindau Tumor Suppressor Protein / Q000502:physiology; D000099162:Endothelial PAS Domain-Containing Protein 1
D000199:Actins; D051792:Basic Helix-Loop-Helix Proteins; D066246:ErbB Receptors; D051966:Phospholipase C gamma; D051794:Von Hippel-Lindau Tumor Suppressor Protein; D000099162:Endothelial PAS Domain-Containing Protein 1; C497446:VHL protein, human
Cancer Metastasis Rev. 2005 Jan;24(1):47-69
15785872
Int J Cancer. 2004 Nov 1;112(2):249-58
15352037
Nat Rev Cancer. 2004 Nov;4(11):891-9
15516961
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
19474385
Exp Cell Res. 2006 Jul 15;312(12):2214-30
16631740
Semin Radiat Oncol. 2009 Jan;19(1):63-8
19028347
Exp Cell Res. 2009 Feb 15;315(4):572-82
18778701
J Clin Oncol. 2008 Jul 1;26(19):3128-37
18474878
Mol Cell Biol. 2003 Dec;23(24):9361-74
14645546
Neoplasia. 2008 Nov;10(11):1295-302
18953439
Cancer Res. 2004 Oct 1;64(19):6845-8
15466170
Cancer Res. 2003 Sep 1;63(17):5629-35
14500405
Nat Med. 2009 Mar;15(3):319-24
19252501
Curr Opin Cell Biol. 2009 Apr;21(2):177-84
19208461
Head Neck. 2005 Jul;27(7):622-38
15952198
Proc Natl Acad Sci U S A. 2009 Dec 15;106(50):21306-11
19955413
PLoS Biol. 2003 Dec;1(3):E83
14691554
J Clin Oncol. 2007 Jun 1;25(16):2164-70
17538160
J Cancer Res Clin Oncol. 2009 Aug;135(8):1047-53
19148680
Genes Dev. 2001 Oct 15;15(20):2675-86
11641274
Cancer Sci. 2005 Jul;96(7):379-86
16053508
J Clin Oncol. 2005 Apr 10;23(11):2445-59
15753456
Cell Metab. 2008 Jan;7(1):11-20
18177721
J Clin Oncol. 2006 Feb 10;24(5):727-35
16418497
Cancer Res. 2004 Feb 15;64(4):1475-82
14983893
Sci STKE. 2007 Aug 21;2007(400):re5
17712139
Nat Rev Cancer. 2008 Nov;8(11):865-73
18923434
Drug Discov Today. 2007 Oct;12(19-20):853-9
17933687
Cancer Res. 2001 Apr 1;61(7):2911-6
11306467
Genes Dev. 2002 Jun 15;16(12):1466-71
12080085
Cancer Lett. 2007 Sep 8;254(2):165-77
17367921
Mol Cancer Ther. 2009 Jul;8(7):1867-77
19584228
Clin Exp Metastasis. 2008;25(4):289-304
18324357
Clin Exp Metastasis. 2003;20(4):285-90
12856715
Curr Opin Genet Dev. 2009 Feb;19(1):60-6
19167211
J Biol Chem. 2003 Nov 7;278(45):44966-74
12944410
Cell. 2000 Jan 7;100(1):57-70
10647931
Cancer Res. 2003 Jun 1;63(11):2948-56
12782602
Nat Clin Pract Oncol. 2007 Mar;4(3):156-71
17327856
J Natl Cancer Inst. 1998 Jun 3;90(11):824-32
9625170
Semin Cancer Biol. 2009 Feb;19(1):12-6
19114105
Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13092-7
17670948
Ann Med. 2004;36(7):530-9
15513303
Br J Radiol. 2006 Oct;79(946):791-8
16854964
Cancer Res. 2005 Jun 15;65(12):5221-30
15958567
J Cell Mol Med. 2009 Sep;13(9A):2780-6
19674190